Ministry of Health, Labour and Welfare
The Japanese ministry that issues the ordinances and ministerial notifications PMDA administers — including the GMP Ordinance (No. 179) — and publishes the Japanese Pharmacopoeia.
What this page does not claim
SPEQ curates and cross-references these bodies. It is not affiliated with, accredited by, or endorsed by any of them, and a count of decoded standards is a measure of SPEQ’s coverage, not of a body’s importance.
WHAT MHLW COVERS
The Ministry of Health, Labour and Welfare is Japan's health ministry and the legal source of its pharmaceutical regulation: the Pharmaceuticals and Medical Devices (PMD) Act is administered under its authority, its ministerial ordinances set the binding requirements — including the GMP Ordinance (MHLW Ordinance No. 179) — and its ministerial notifications issue the Japanese Pharmacopoeia, currently the 18th Edition (Notification No. 220, effective 7 June 2021, supplemented through Notification No. 238 of 28 June 2024). MHLW and PMDA are distinct bodies deliberately kept so in SPEQ's registry: the ministry legislates, notifies, and holds the legal authority; the PMDA is the agency that administers reviews, inspections, and safety operations under it.
WHAT MHLW PUBLISHES
- 01Ministerial ordinances under the PMD Act — including the GMP Ordinance (No. 179) and the QMS Ordinance for devices
- 02The Japanese Pharmacopoeia, issued by ministerial notification (JP XVIII: No. 220; Supplement II: No. 238)
- 03Ministerial notifications and administrative notices interpreting the ordinances
- 04The PMD Act framework itself, as amended through Diet legislation the ministry administers
HOW ITS REQUIREMENTS BITE
Rule-making at the ministry, administration through the agency and the prefectures. MHLW issues the ordinances and notifications that carry legal force; PMDA conducts scientific review and GMP inspections on the ministry's behalf, prefectural governments license and inspect domestic sites, and marketing authorisations are granted in the ministry's name. Compendial standards acquire force the same way: the JP is issued by ministerial notification under the PMD Act, and drugs the pharmacopoeia covers must comply with it as a condition of the Japanese market.
What practitioners get wrong
- Attribute correctly: the JP and the ordinances are MHLW instruments; PMDA administers them. Dossiers and SOPs citing "PMDA requirements" for what is ministry law invert the hierarchy.
- The JP supplement stream (not just the edition) is the binding current state — Japan-market specifications must track ministerial notifications as they land.
- GMP obligations flow from Ordinance No. 179 as a condition of marketing approval, with PMDA and prefectural inspections enforcing it — foreign sites are inspected too.
- The official English JP is free via PMDA, but the Japanese text is the legal original; discrepancies resolve to the Japanese.
WHERE IT SITS INTERNATIONALLY
Japan is an ICH founding member and a PIC/S participant through its authorities, and the JP is one of the three Pharmacopoeial Discussion Group compendia working toward harmonised texts with the USP and Ph. Eur. The MHLW–PMDA split mirrors a common international pattern — ministry as legal authority, agency as scientific administrator — comparable to the European Commission's relationship with the EMA.
MHLW STANDARDS SPEQ DECODES · 2
DISCIPLINES IN MHLW’S REMIT
MHLW: frequently asked questions
Reference answers on Ministry of Health, Labour and Welfare’s mandate, what it publishes, and how its requirements acquire force.
What is the difference between MHLW and PMDA?
MHLW is the ministry: it holds legal authority under the PMD Act, issues the binding ordinances (including GMP Ordinance No. 179), and publishes the Japanese Pharmacopoeia by ministerial notification. PMDA is the administrative agency that performs reviews, GMP inspections, and safety operations under that authority.
Who publishes the Japanese Pharmacopoeia?
MHLW, by ministerial notification — the 18th Edition by Notification No. 220 (effective 7 June 2021), with Supplement II issued by Notification No. 238 on 28 June 2024. The PMDA hosts the free official English translation.
Is the Japanese Pharmacopoeia legally binding?
Yes. Under the PMD Act, drugs covered by JP monographs must meet the compendial standards for the Japanese market — the JP plays the same structural role there that the USP and Ph. Eur. play in their jurisdictions.